{"filing":{"accession_number":"0001104659-26-091099","cik":"0001377121","ticker":"PTGX","company_name":"Protagonist Therapeutics, Inc","form":"8-K","filing_date":"2026-08-05","report_date":"2026-08-05","primary_document":"tm2622272d1_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465926091099/tm2622272d1_8k.htm"},"events":[{"id":24400,"run_id":22107,"accession_number":"0001104659-26-091099","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.97,"summary":"Protagonist Therapeutics reported Q2 2026 financial results with license and collaboration revenue of $213.5 million (versus $5.5 million in Q2 2025), net income of $162.8 million (versus a net loss of $34.8 million in the prior year), and earnings per share of $2.47 basic and $2.29 diluted. The earnings release and corporate update were furnished as exhibits to the 8-K.","company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":24940,"accession_number":"0001104659-26-091099","item_number":"2.02","item_title":"Results of Operations","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Protagonist's financial results for Q2 2026 (quarter ended June 30, 2026). The filing includes consolidated statements of operations showing license and collaboration revenue of $213.5 million for Q2 2026 versus $5.5 million in Q2 2025, net income of $162.8 million versus a net loss of $34.8 million in the prior year, and earnings per share of $2.47 basic and $2.29 diluted. The press release titled \"Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update\" is furnished as Exhibit 99.1 and is the core disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:32:36.515049+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24941,"accession_number":"0001104659-26-091099","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1) contain a comprehensive earnings release titled \"Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update\" dated August 5, 2026. The release includes detailed financial statements (consolidated statements of operations), per-share earnings ($2.47 basic, $2.29 diluted for Q2 2026), revenue breakdowns, and operating expense details. This constitutes a material earnings disclosure for the second quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:32:36.515049+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24940,"accession_number":"0001104659-26-091099","item_number":"2.02","item_title":"Results of Operations","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"This is a clear earnings release disclosing Protagonist's financial results for Q2 2026 (quarter ended June 30, 2026). The filing includes consolidated statements of operations showing license and collaboration revenue of $213.5 million for Q2 2026 versus $5.5 million in Q2 2025, net income of $162.8 million versus a net loss of $34.8 million in the prior year, and earnings per share of $2.47 basic and $2.29 diluted. The press release titled \"Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update\" is furnished as Exhibit 99.1 and is the core disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:32:36.515049+00:00","company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","filing_date":"2026-08-05"},{"id":24941,"accession_number":"0001104659-26-091099","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"The Item 7.01 disclosure references an updated corporate presentation, but the supplemental exhibits (EX-99.1) contain a comprehensive earnings release titled \"Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update\" dated August 5, 2026. The release includes detailed financial statements (consolidated statements of operations), per-share earnings ($2.47 basic, $2.29 diluted for Q2 2026), revenue breakdowns, and operating expense details. This constitutes a material earnings disclosure for the second quarter ended June 30, 2026.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-06T02:32:36.515049+00:00","company_name":"Protagonist Therapeutics, Inc","ticker":"PTGX","filing_date":"2026-08-05"}]}